Bionyra Pharma Raises $165M in Series A Funding

The round also saw participation from Arkin Bio, Sanofi Ventures, Sixty Degree Capital, Vives Partners and Apollo Health Ventures.

The company plans to use the funds to grow its business operations and invest in research and development activities.

Bionyra is developing next-generation antibody therapies, including single-target and multi-target antibodies, for diseases that still have significant unmet medical needs despite existing treatments. Its research is focused on conditions such as atopic dermatitis and inflammatory bowel disease (IBD).

Read More:Hemlo Mining Corp. Appoints Eva Koci to Board of Directors

The company has licensed BYN-002 and BYN-003 from TrueLab Biopharmaceutical and BYN-001 from NovaRock Biotherapeutics, securing exclusive global rights outside Greater China. In addition, Bionyra is advancing several other innovative preclinical drug candidates, including programs licensed from TrueLab.

Bionyra is launching with a broad pipeline of next-generation anti-inflammatory therapies aimed at delivering innovative treatments for patients. The company is developing therapies that combine multiple biological targets with improved drug design to enhance effectiveness and patient outcomes. Its lead candidates focus on inflammatory diseases such as inflammatory bowel disease (IBD), atopic dermatitis, and other immune-related conditions.

The pipeline includes BYN-002, a TL1A monoclonal antibody for IBD and related diseases that has completed enrollment in a Phase 1 study; BYN-003, a TL1A and IL-23p19 bispecific antibody that entered clinical testing in April and is currently in a Phase 1 study; and BYN-001, an IL-25 monoclonal antibody in the IND stage of development for atopic dermatitis and other Type 2 inflammatory diseases.

“More than half of patients suffering from immune-mediated inflammatory diseases remain inadequately controlled, highlighting a significant need for better treatment options. Across our pipeline, we are selectively modulating immune pathways that are central drivers of disease in indications where current therapies remain insufficient,” said Dr. Marrache, Co-founder and CEO of Bionyra. “We have built Bionyra around assets and targets with clear therapeutic rationale, relevant biology and optimized clinical strategy to develop therapies that will deliver meaningful impact to people who don’t currently have good options.”

“So many patients suffering from immune-mediated inflammatory diseases still face daily burden due to limited treatment options,” said Mehdi Ainouche, Partner at Jeito Capital. “Bionyra is uniquely positioned to accelerate delivery of highly promising therapies to patients through a focused and well-designed clinical development strategy aimed at rapidly generating clinical validation and addressing key unmet needs like deeper remission and alternatives for non-responders.

“When we co-founded Bionyra with Frédéric, our conviction in both the company and his leadership was grounded in his deep expertise in immune and inflammatory diseases. Today, that conviction is reflected in a $165 million oversubscribed round backed by an exceptional syndicate of investors who share our belief in this pipeline and the team behind it. Looking ahead, we are focused on advancing these programs with the aim of bringing meaningful new treatment options to patients,” said Anta Gkelou, Partner at Sofinnova Partners.

About Bionyra Pharma

Founded in 2025, Bionyra Pharma is a clinical stage biopharmaceutical company focused on developing advanced biologic therapies for severe immune and inflammatory diseases. The company is working on next generation monoclonal and multispecific antibodies designed to target new immune pathways and provide longer lasting disease control through half-life extension technology.

Read More:Cole Palmer Partners With Gopuff to Launch COLE’D